Oragenics (NYSE:OGEN) Now Covered by StockNews.com

Research analysts at StockNews.com assumed coverage on shares of Oragenics (NYSE:OGEN) in a research note issued to investors on Saturday. The firm set a “sell” rating on the stock.

Oragenics Price Performance

Shares of NYSE:OGEN opened at $1.12 on Friday. Oragenics has a 52-week low of $0.97 and a 52-week high of $7.74. The firm has a market cap of $5.00 million, a P/E ratio of -0.13 and a beta of 0.50. The firm has a 50-day moving average price of $1.61.

Oragenics (NYSE:OGEN) last issued its earnings results on Wednesday, May 15th. The company reported ($0.70) earnings per share (EPS) for the quarter.

Institutional Investors Weigh In On Oragenics

An institutional investor recently bought a new position in Oragenics stock. Virtu Financial LLC bought a new position in shares of Oragenics, Inc. (NYSE:OGEN) during the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm bought 22,675 shares of the company’s stock, valued at approximately $33,000. Virtu Financial LLC owned 0.51% of Oragenics at the end of the most recent quarter. Hedge funds and other institutional investors own 18.71% of the company’s stock.

Oragenics Company Profile

Oragenics, Inc, a development-stage company, engages in the research and development of antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus.